Aonong Bio released its 2026 interim report. The company's total operating revenue was 4.521 billion yuan, and net profit attributable to the parent company was negative 190 million yuan, swinging from profit to loss. This was a decrease of 551 million yuan compared with the same period last year, a year-on-year decline of 152.61 percent. Net cash flow from operating activities was negative 329 million yuan, a decrease of 12.5302 million yuan compared with the same period last year. The company's asset-liability ratio was 62.08 percent, gross margin was 1.67 percent, return on equity was negative 6.41 percent, and diluted earnings per share was negative 0.07 yuan. The number of shareholders was 84,500, and the top ten shareholders held 43.12 percent of the total share capital.
Fujian Aonong Biological Technology Group Incorporation LtdNet loss of 190 million yuan, swinging from profit to loss, with revenue and cash flow declining.
